flow trial semaglutide kidney outcomes nejm 2024 hazard ratio 0.76 reduced the risk of clinically important and death from cardiovascular (CV) causes in patients with type 2 diabetes (T2D) and CKD ca. #ERA24 🇸🇪 #Nephpearls https://www.nejm .org/doi/full/10.1056/NEJMoa2403347 Effects of Semaglutide on Chronic

Regular Follow-Up Scheduled visits and virtual check-ins help monitor your progress, answer questions, and make timely adjustments for your safety and satisfaction

Unlike Wegovy, orforglipron has fewer restrictions around timing

This includes but is not limited to, conducting checkups and asking questions over the phone and video chat options, handling simple advisory medical tasks over virtual platforms, and even administering medical care via services that can meet you at home or direct you to nearby resources

The choice depends on your rebound risk (assessed via Precision Peptide Genetic Test), lifestyle preferences, and budget